Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    A blood test for antibodies will show if you have been exposed to hepatitis C.HIV treatment has particular benefits for people with HIV and hepatitis...

    From: Factsheets

    Information level Level 2
  • Hepatitis C treatment

    Effective treatments are available for hepatitis C. This field is evolving rapidly and standards of care are changing. The newest drugs can cure most people with hepatitis...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    The old standard of care for hepatitis C treatment for all HCV genotypes was pegylated interferon and ribavirin. Interferon works by stimulating immune system activity against HCV. There...

    From: Booklets

    Information level Level 2
  • Hepatitis C treatment for people with co-infection

    Current guidelines recommend that you start hepatitis C treatment if you have HIV and HCV co-infection with moderate or worse liver fibrosis (stage F2 to F4) and...

    From: Booklets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

  • Indonesian buyers club helps people obtain generic hepatitis C treatment

    A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral (DAA) drugs to treat hepatitis C and is seeing a high cure rate, according to a presentation at the 25th International Harm Reduction ...

    24 May 2017 | Liz Highleyman
  • Hepatitis C virus reinfection is uncommon after being cured with DAAs

    Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during three years of follow-up, researchers reported yesterday at the 25th International Harm ...

    19 May 2017 | Liz Highleyman
  • Triple combination cures most hepatitis C patients with prior DAA treatment failure

    Almost all people with genotype 1 hepatitis C who were previously unsuccessfully treated with a course of interferon-free direct-acting antiviral therapy achieved sustained response when retreated with a three-drug combination being developed by Merck, researchers reported at the International Liver ...

    28 April 2017 | Liz Highleyman
  • Generic hepatitis C drugs continue to produce high cure rates

    Treatment with generic versions of direct-acting antiviral drugs continues to produce similar cure rates to those reported in clinical trials, Dr James Freeman reported last week at the International Liver Congress in Amsterdam.Dr James Freeman, an ...

    24 April 2017 | Keith Alcorn
  • AbbVie combination cures 95% of genotype 3 hepatitis C

    AbbVie's pangenotypic direct-acting antiviral combination of two drugs cured 95% of people with early-stage genotype 3 hepatitis C virus (HCV), the hardest genotype to treat, according to results of the ENDURANCE-3 trial presented at the International ...

    21 April 2017 | Keith Alcorn
  • New AbbVie hepatitis C combination cures 99% of people with cirrhosis

    A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side-effects, Xavier Forns reported on behalf of ...

    21 April 2017 | Keith Alcorn
  • Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies

    People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable ...

    21 April 2017 | Liz Highleyman
  • European HCV treatment access survey shows big variations in eligibility

    England, Malta, Slovakia, Hungary and Croatia have the tightest restrictions on who can receive direct-acting antiviral (DAA) treatment for hepatitis C, while France, Ireland, Portugal, Germany, Poland and the Netherlands are the least restrictive, research presented today at the International ...

    20 April 2017 | Keith Alcorn
  • Curing hepatitis C reduces cardiovascular risk

    Curing hepatitis C reduces the risk of cardiovascular events in people with compensated cirrhosis, a large French study presented this week at the International Liver Congress in Amsterdam shows. Presenting the findings, Patrice Cacoub of Hôpital Pitié-Salpêtrière, Paris, stressed the ...

    20 April 2017 | Keith Alcorn
  • Hepatitis C treatment can be provided successfully at syringe programme sites

    Administering direct-acting antiviral therapy for people who inject drugs at a syringe exchange site led to high sustained response rates in a pilot study in New York City, researchers reported at the recent Conference on Retroviruses and Opportunistic Infections ...

    19 April 2017 | Liz Highleyman
More news

Hepatitis C treatment news selected from other sources

  • China captures 12 smugglers of Indian pharmaceuticals

    Chinese police have detained 12 people for smuggling and selling Indian-made treatments for hepatitis C and cancer, authorities said Wednesday.

    24 May 2017 | Xinhua
  • Costs for generic hepatitis C drugs available in India would be paid back in 5 to 10 years

    Use of the generic versions of directly-acting antiviral drugs that are available in India to treat hepatitis C virus infection is not only cost effective but actually saves lifetime costs for treating infected patients in that country.

    18 May 2017 | Eurekalert Inf Dis
  • Surgeons plan to use hepatitis-infected hearts to slash wait for a transplant

    As many as 1,000 such infected kidneys are thrown away each year in the United States, but new medications have made hepatitis C curable — and made it possible to consider using infected organs for transplants. That could cut down on the wait time not just for kidneys but also other organs, especially hearts.

    15 May 2017 | STAT
  • Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan-genotypic Regimen for Chronic Hepatitis C in UK

    The UK scheme makes glecaprevir/pibrentasvir available to people with compensated cirrhosis and prior treatment with an NS5A inhibitor (genotypes 1, 4, 5 or 6), chronic kidney disease (genotypes 2, 3, 5 or 6) or genotype 3 with previous exposure to pegylated interferon, ribavirin and/or sofosbuvir.

    10 May 2017 | AbbVie press release
  • BC-developed hepatitis C screening test personalizes treatment for patients

    Scientists in Vancouver have developed a new screening tool that reveals the genetic signature of an individual’s hepatitis C virus so that doctors can customize their treatment.

    10 May 2017 | The Globe and Mail
  • Louisiana proposes tapping a century-old patent law to cut hepatitis C drug prices

    Continuing public concerns over high-priced hepatitis C drugs are taking a new twist as Louisiana’s top health official proposes using an obscure federal patent law to get the medicines at a much lower cost. If successful, other states could reap the benefits.

    03 May 2017 | Washington Post
  • New website launched to help prevent spread of hepatitis C

    A group of researchers launched a new website Wednesday that lays out a roadmap to curb the spread of hepatitis C. HepVu is the result of a public-private partnership aimed to help the estimated 3.9 million Americans who currently have or have had hepatitis C

    28 April 2017 | ModernHealthcare.com
  • Top 10 Pharmaceutical Companies 2017

    The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

    18 April 2017 | LinkedIn
  • Hepatitis drug patent application opposed

    A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property's Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair competition by precluding the development and distribution of generic versions of Sofosbuvir at lower prices, said a group of 30 activists led by the Aids Access Foundation and Thai Network of People Living with HIV/Aids.

    12 April 2017 | Bangkok Post
  • WHO prequalifies first generic active ingredient for hepatitis C medicines

    On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - India.

    05 April 2017 | World Health Organization
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.